Approval Probability 71%
TA Base Rate26%
Adjusted LOA41%
ML RiskLOW_RISK
| NCT ID | Title | Phase | Status | Enrollment | Velocity | Design | Start | Completion | Last Updated | Sites | Countries |
|---|---|---|---|---|---|---|---|---|---|---|---|
| NCT07136285 | Olvi-Vec Combined With Platinum Plus Etoposide Therapy in Patients With Late Phase SCLC | PHASE1 | RECRUITING | 27 | — | — | Jul 24, 2023 | Dec 1, 2026 | Dec 3, 2025 | 2 | China |
Frequency and severity of adverse events measured according to NCI Common Toxicity Criteria Adverse Event (CTCAE), version 5.0
| Arm | Type | Description |
|---|---|---|
| Experimental | EXPERIMENTAL | Olvi-Vec will be administered for 3 days in C1, then starting from C2, platinum (platinum (cisplatin or carboplatin)) and episode are administrated each 21 days till patients could not tolerate. |
| Name | Type | Description |
|---|---|---|
| Olvi-Vec | DRUG | Olvi-Vec will be administered to patient for 3 days during C1 |
| platinum (cisplatin or carboplatin) | DRUG | After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Platinum （Carboplatin or Cisplatin）will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred. |
| Etoposide | DRUG | After completing the first cycle of treatment of Olvi-Vec (+21 days after the last dose), Etoposide will be administrated on D1,D2 and D3 each 21 days (dosage according to the label) from Cycle 2 until disease progression or intolerable toxicity occurred. |
Inclusion Criteria: * Able to understand and voluntarily sign an informed consent form. * Age ≥ 18 years old, gender not limited. * Small cell lung cancer confirmed by organization or cytology. * After receiving platinum based chemotherapy regimens and/or immunotherapy, platinum based chemotherapy ...